Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of ...
Acadia Pharmaceuticals isn’t taking its recent rejection from the European Medicines Agency lying down, vowing to seek a re-examination of the decision from the regulator's Committee for Medicinal | ...
Researchers show two distinct MECP2 mutations in Rett syndrome elevate miRNA-126-3p, lowering ZO-1 and weakening blood-brain ...
Neurogene received FDA Breakthrough Therapy Designation for NGN-401 in Rett Syndrome, driving a >25% share price surge. Click ...
Daybue was turned down for Rett syndrome, and Iloperidone for schizophrenia and bipolar I, with safety and benefit-risk concerns cited in both cases.
A European regulatory body adopted a negative opinion regarding Acadia Pharmaceuticals' application for trofinetide, its treatment for Rett syndrome, a rare neurodevelopmental disorder seen in ...
Evox Therapeutics Ltd ("Evox" or the "Company"), a biotechnology company developing innovative therapies for genetically driven neurodegenerative diseases using a next-generation gene editing modality ...
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) will request a re-examination of a negative opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) on its ...
Neuroscientists discover that Rett syndrome mutations cause a leaky brain via overexpressed miRNA-126-3p, pointing to a new therapeutic target for vascular repair.
Taysha Gene Therapies Inc. is set to report fourth-quarter results on Wednesday, as investors weigh the clinical-stage biotech’s deepening losses against progress in its lead gene therapy program for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results